Avecho Biotechnology Ltd banner

Avecho Biotechnology Ltd
ASX:AVE

Watchlist Manager
Avecho Biotechnology Ltd Logo
Avecho Biotechnology Ltd
ASX:AVE
Watchlist
Price: 0.009 AUD Market Closed
Market Cap: AU$33.1m

Avecho Biotechnology Ltd
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Avecho Biotechnology Ltd
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Avecho Biotechnology Ltd
ASX:AVE
Research & Development
-AU$3.7m
CAGR 3-Years
-22%
CAGR 5-Years
-99%
CAGR 10-Years
-3%
Recce Pharmaceuticals Ltd
ASX:RCE
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mayne Pharma Group Ltd
ASX:MYX
Research & Development
-AU$17.9m
CAGR 3-Years
-14%
CAGR 5-Years
4%
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Research & Development
-AU$30m
CAGR 3-Years
-58%
CAGR 5-Years
-33%
CAGR 10-Years
-9%
C
Clarity Pharmaceuticals Ltd
ASX:CU6
Research & Development
-AU$66.9m
CAGR 3-Years
-52%
CAGR 5-Years
-57%
CAGR 10-Years
N/A
Nyrada Inc
ASX:NYR
Research & Development
-AU$4.4m
CAGR 3-Years
-34%
CAGR 5-Years
-26%
CAGR 10-Years
N/A
No Stocks Found

Avecho Biotechnology Ltd
Glance View

Market Cap
33.1m AUD
Industry
Pharmaceuticals

Avecho Biotechnology Ltd. engages in the development, production, sale, and licensing of products incorporating its patented platform technology, Targeted Penetration Matrix (TPM), for the pharmaceutical, skin care and animal health and nutrition industries. The company is headquartered in Melbourne, Victoria. The firm's products pipeline includes Weaner Pig Starter TPM premix, Poultry TPM, Dairy TPM, and Veterinary Applications. The firm's segments include Production and Personal Care and Human Health. The Production and Personal Care segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches. The Human Health segment focuses on the development of patches, including TPM/Oxymorphone, TPM/enhanced, and TPM/Oxycodone. Its TPM products are commercialized under license Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.

AVE Intrinsic Value
0.006 AUD
Overvaluation 34%
Intrinsic Value
Price

See Also

What is Avecho Biotechnology Ltd's Research & Development?
Research & Development
-3.7m AUD

Based on the financial report for Jun 30, 2025, Avecho Biotechnology Ltd's Research & Development amounts to -3.7m AUD.

What is Avecho Biotechnology Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
-3%

Over the last year, the Research & Development growth was -27%. The average annual Research & Development growth rates for Avecho Biotechnology Ltd have been -22% over the past three years , -99% over the past five years , and -3% over the past ten years .

Back to Top